...
首页> 外文期刊>Bone marrow transplantation >Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality
【24h】

Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality

机译:重症监护单位的批判性异常的HSCT患者:对死亡率的预后因素进行系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Outcome of patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) has improved. To investigate if this improvement can be transposed to the ICU setting, we conducted a systematic review and meta-analysis to assess short-term mortality of critically ill allo-HSCT patients admitted to the ICU and to identify prognostic factors of mortality. Public-domain electronic databases, including Medline via PubMed and the Cochrane Library were searched. All full-text articles written-English studies published from 2006 to 2016, including allo-HSCT adults transferred to the ICU were included. Eighteen studies were selected, including 2342 patients. Overall estimated ICU mortality was 51.7%. Prognostic factors associated with an increased ICU mortality were mechanical ventilation (OR = 12.2, 95% CI = 6.2-23.7), vasopressors (OR = 6.3, 95% CI = 3.6-11.1), renal replacement therapy (OR = 4.2, 95% CI = 2.8-6.2), ICU admission for acute respiratory failure (OR = 2.2, 95% CI = 1.1-4.4), acute kidney injury (OR = 2.2, 95% CI = 1.3-4), and acute graftversus- host disease (OR = 1.6, 95% CI = 1.1-2.3). Factors associated with an increased ICU survival were a single-organ failure (OR = 0.2, 95% CI = 0.1-0.4), neurological failure (OR = 0.4, 95% CI = 0.2-0.8), and reduced-intensity conditioning regimens (OR = 0.7, 95% CI = 0.5-0.9). Septic shock, underlying malignancy, disease status, donor, and graft source did not impact prognosis. Outcome has improved, supporting the usefulness of ICU management. Organ failures at ICU admission, organ support requirement, and GVHD are the main prognostic factors.
机译:接受同种异体造血干细胞移植(Allo-HSCT)的患者的结果提高。为了调查这种改进可以转移到ICU环境,我们进行了系统的评价和荟萃分析,以评估承认ICU的批评性allo-HSCT患者的短期死亡率,并确定死亡率的预后因素。搜索公共域电子数据库,包括通过Pubmed和Cochrane图书馆的Medline。所有全文文章的书面文章从2006年到2016年出版的全文文章研究,包括转让给ICU的Allo-HSCT成年人。选择了18项研究,包括2342名患者。总体估计的ICU死亡率为51.7%。与ICU增长的预后因素是机械通气(或= 12.2,95%CI = 6.2-23.7),血管加压剂(或= 6.3,95%CI = 3.6-11.1),肾置换疗法(或= 4.2,95% CI = 2.8-6.2),ICU入院急性呼吸衰竭(OR = 2.2,95%CI = 1.1-4.4),急性肾损伤(或= 2.2,95%CI = 1.3-4),以及急性包覆染症 - 宿主病(或= 1.6,95%CI = 1.1-2.3)。与ICU增加相关的因素是单器官失效(或= 0.2,95%CI = 0.1-0.4),神经故障(或= 0.4,95%CI = 0.2-0.8),以及减少强度调理方案(或= 0.7,95%CI = 0.5-0.9)。化粪池休克,潜在的恶性肿瘤,疾病状态,供体和移植源没有影响预后。结果有所改善,支持ICU管理的有用性。 ICU入院的器官失败,器官支持要求和GVHD是主要的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号